The saga continues here in Australia where the Australian Competitor and Consumer Commission (ACCC) has logged an appeal to the Federal Court over their anti-competitive case against Pfizer.
This all stems back to early 2012 as the patent for Lipitor, a large market in Australia, was coming up to its expiry. The conduct in question being Pfizer’s dealings with pharmacy over Lipitor and their generic atorvastatin product. The allegations stated that Pfizer had misused its market power to engage in exclusively dealings designed to lessen competition.
We know the patent expiry for Lipitor affected pharma in all different ways around the world and now, in 2015, the issues is still current. Stay tuned for an update on the next stage of this Federal case.
How did this issue affect you in your market?
What’s the next drug coming off-patent that you think will affect the market?
